Eurystatin B
Alternative Names: BU 4164E-BLatest Information Update: 02 Jul 2001
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Prolyl endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 02 Jul 2001 No-Development-Reported for Alzheimer's disease in Japan (Unknown route)
- 01 Jun 1995 Preclinical development for Alzheimer's disease in Japan (Unknown route)